MAPT and Alzheimer disease: In summary, we have established that the commonly used RA drug, HCQ lowers AD risk in older individuals, and targets multiple pathogenic mechanisms in AD including synaptic dysfunction, neuroinflammation, Aβ clearance, and tau phosphorylation.